Icalcaprant

Last updated
Icalcaprant
Icalcaprant.png
Clinical data
Other namesCVL-354
Routes of
administration 		Oral administration
Drug class Opioid antagonist; κ-Opioid receptor antagonist
Identifiers
  • 4-[4-{{(2S)-2-(3-methoxy-1-methylpyrazol-4-yl)pyrrolidin-1-yl]methyl]phenoxy]benzamide
CAS Number
PubChem CID
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C23H26N4O3
Molar mass 406.486 g·mol−1
3D model (JSmol)
  • CN1C=C(C(=N1)OC)[C@@H]2CCCN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)N
  • InChI=1S/C23H26N4O3/c1-26-15-20(23(25-26)29-2)21-4-3-13-27(21)14-16-5-9-18(10-6-16)30-19-11-7-17(8-12-19)22(24)28/h5-12,15,21H,3-4,13-14H2,1-2H3,(H2,24,28)/t21-/m0/s1
  • Key:OBDLEFCGVHQDFR-NRFANRHFSA-N

Icalcaprant [1] (developmental code name CVL-354) is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders. [2] [3] It is taken by mouth. [2]

It acts as a selective antagonist of the κ-opioid receptor. [2] [3] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor. [3]

It was originated by Pfizer and is under development by Cerevel Therapeutics (a subsidiary of AbbVie). [2] [4] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders. [2]

See also

References

  1. ↑ "Icalcaprant (CVL-354)". AbbVie . Retrieved 2024-08-15.
  2. 1 2 3 4 5 "CVL 354 – Cerevel therapeutics". Adis Insight. Springer Nature Switzerland AG.
  3. 1 2 3 "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN   1740-634X. PMC   9714399 . PMID   36456694.
  4. ↑ "AbbVie Completes Acquisition of Cerevel Therapeutics". AbbVie News Center. Retrieved 2025-05-07.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.